Substantial evidence has established EGFR-TKIs as the superior first-line therapy for patients with EGFR-mutated NSCLC, and clearly illustrates the importance of CGP in the guidance of treatment regimens and subsequent impact on patient care43. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.